2026 Q2 -tulosraportti
30 päivää sitten
‧48 min
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 -tulosraportti 28.10. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 -tulosraportti 29.7. | ||
2026 Q1 -tulosraportti 7.5. | ||
2025 Q4 -tulosraportti 18.2. | ||
2025 Q3 -tulosraportti 29.10.2025 | ||
2025 Q2 -tulosraportti 30.7.2025 |
Asiakkaat katsoivat myös
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·1 päivä sittenAsieris Pharmaceuticals’ portable, flexible blue light cystoscope APLD-2304 receives EU CE mark August 2026 Press Release Shanghai, China, August 27, 2026 — Asieris Pharmaceuticals (stock code: 688176.SH), a global, innovative pharmaceutical company focusing on genitourinary tumors and women's health, announced that its independently developed, portable, flexible blue light cystoscope APLD-2304 has recently received the EU MDR CE mark, granting market access in the EU. APLD-2304 is the world's first portable, flexible, single-use blue light cystoscope, developed by the company to meet the clinical needs and usage scenarios for bladder cancer diagnosis and follow-up monitoring[1]. Driven by an aging population and high smoking rates, Europe faces a high annual incidence of bladder cancer, exceeding 130,000 new cases[2]. The high recurrence rate of the disease creates a large unmet need for long-term postoperative patient monitoring. APLD-2304 leverages the advantage of blue light imaging to identify tiny lesions and carcinoma in situ, and has significant potential in the bladder cancer monitoring market. In clinical practice in Europe and the US, white light cystoscopy is often used for the diagnosis and follow-up of bladder cancer. However, it often fails to detect flat or small peripheral lesions in the early stage, leading to low detection rates and high recurrence rates. The company's APLD 2304, used in combination with a blue light imaging agent Hexvix®, forms an integrated diagnostic solution for bladder cancer drugs. This solution improves the detection rate of bladder cancer, reduces the recurrence rate for patients, and its portable, flexible, sterile single-use design provides greater convenience for doctors, improves patient comfort during surgical procedures, and reduces the risk of cross-infection. This CE certification for APLD 2304 was issued by the EU's notified body (BSI Group The Netherlands B.V.) in accordance with the certification rules of the Medical Device Regulation (MDR), along with a quality system certificate according to ISO 13485:2016. This is the first time a company-developed product has received regulatory registration in the EU, meaning that Asieris has established a quality management system for medical devices that complies with EU MDR requirements. APLD 2304 meets the latest criteria for market access in the EU and can be sold in regions that recognize EU medical device regulations. In addition, APLD-2304 has full independent intellectual property rights, and several patent applications for this product have been filed both nationally and internationally. Richard Zhao, Senior Vice President of Business Development at Asieris Pharmaceuticals, stated: "The EU CE mark for APLD 2304 is an important step in our strategic focus on specialized clinical fields and our comprehensive planning for holistic bladder cancer treatment. It also underscores Asieris’ strong commitment to addressing critical unmet global clinical needs. We will continue to drive the development of clinical treatment protocols, deliver innovative solutions for patients, and elevate the diagnostic and therapeutic standards for bladder cancer."
·3 päivää sittenCan someone give me motivation to stay🙏 it's a bit dark here these days
- Reclassification in the USA will make the available market 12x larger. - New 4K HD-flex scope ready from 2027. - AssureMDx sales from 2027, and has several viable paths to reimbursement during 2027. - Cevira sales broadly underway in China with reimbursement most likely in place from January 2027. Approval in Europe in 2027. - Insiders and largest owner are increasing their positions after Asieris files a counterclaim. Should say enough about what they think it's heading towards. - After many years of lukewarm guidances from management, they have finally guided "high-teens" to 25% annual growth, and this was excluding reclassification. Find it very exciting to be PHO-invested at the moment.
·24.8.Things are loosening up soon for PHO. Downgrade in US As well as important validations of Cevira are the start of a strong repricing https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2026.1899399/full
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2026 Q2 -tulosraportti
30 päivää sitten
‧48 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·1 päivä sittenAsieris Pharmaceuticals’ portable, flexible blue light cystoscope APLD-2304 receives EU CE mark August 2026 Press Release Shanghai, China, August 27, 2026 — Asieris Pharmaceuticals (stock code: 688176.SH), a global, innovative pharmaceutical company focusing on genitourinary tumors and women's health, announced that its independently developed, portable, flexible blue light cystoscope APLD-2304 has recently received the EU MDR CE mark, granting market access in the EU. APLD-2304 is the world's first portable, flexible, single-use blue light cystoscope, developed by the company to meet the clinical needs and usage scenarios for bladder cancer diagnosis and follow-up monitoring[1]. Driven by an aging population and high smoking rates, Europe faces a high annual incidence of bladder cancer, exceeding 130,000 new cases[2]. The high recurrence rate of the disease creates a large unmet need for long-term postoperative patient monitoring. APLD-2304 leverages the advantage of blue light imaging to identify tiny lesions and carcinoma in situ, and has significant potential in the bladder cancer monitoring market. In clinical practice in Europe and the US, white light cystoscopy is often used for the diagnosis and follow-up of bladder cancer. However, it often fails to detect flat or small peripheral lesions in the early stage, leading to low detection rates and high recurrence rates. The company's APLD 2304, used in combination with a blue light imaging agent Hexvix®, forms an integrated diagnostic solution for bladder cancer drugs. This solution improves the detection rate of bladder cancer, reduces the recurrence rate for patients, and its portable, flexible, sterile single-use design provides greater convenience for doctors, improves patient comfort during surgical procedures, and reduces the risk of cross-infection. This CE certification for APLD 2304 was issued by the EU's notified body (BSI Group The Netherlands B.V.) in accordance with the certification rules of the Medical Device Regulation (MDR), along with a quality system certificate according to ISO 13485:2016. This is the first time a company-developed product has received regulatory registration in the EU, meaning that Asieris has established a quality management system for medical devices that complies with EU MDR requirements. APLD 2304 meets the latest criteria for market access in the EU and can be sold in regions that recognize EU medical device regulations. In addition, APLD-2304 has full independent intellectual property rights, and several patent applications for this product have been filed both nationally and internationally. Richard Zhao, Senior Vice President of Business Development at Asieris Pharmaceuticals, stated: "The EU CE mark for APLD 2304 is an important step in our strategic focus on specialized clinical fields and our comprehensive planning for holistic bladder cancer treatment. It also underscores Asieris’ strong commitment to addressing critical unmet global clinical needs. We will continue to drive the development of clinical treatment protocols, deliver innovative solutions for patients, and elevate the diagnostic and therapeutic standards for bladder cancer."
- ·3 päivää sittenCan someone give me motivation to stay🙏 it's a bit dark here these days- Reclassification in the USA will make the available market 12x larger. - New 4K HD-flex scope ready from 2027. - AssureMDx sales from 2027, and has several viable paths to reimbursement during 2027. - Cevira sales broadly underway in China with reimbursement most likely in place from January 2027. Approval in Europe in 2027. - Insiders and largest owner are increasing their positions after Asieris files a counterclaim. Should say enough about what they think it's heading towards. - After many years of lukewarm guidances from management, they have finally guided "high-teens" to 25% annual growth, and this was excluding reclassification. Find it very exciting to be PHO-invested at the moment.
- ·24.8.Things are loosening up soon for PHO. Downgrade in US As well as important validations of Cevira are the start of a strong repricing https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2026.1899399/full
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 -tulosraportti 28.10. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 -tulosraportti 29.7. | ||
2026 Q1 -tulosraportti 7.5. | ||
2025 Q4 -tulosraportti 18.2. | ||
2025 Q3 -tulosraportti 29.10.2025 | ||
2025 Q2 -tulosraportti 30.7.2025 |
2026 Q2 -tulosraportti
30 päivää sitten
‧48 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 -tulosraportti 28.10. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 -tulosraportti 29.7. | ||
2026 Q1 -tulosraportti 7.5. | ||
2025 Q4 -tulosraportti 18.2. | ||
2025 Q3 -tulosraportti 29.10.2025 | ||
2025 Q2 -tulosraportti 30.7.2025 |
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·1 päivä sittenAsieris Pharmaceuticals’ portable, flexible blue light cystoscope APLD-2304 receives EU CE mark August 2026 Press Release Shanghai, China, August 27, 2026 — Asieris Pharmaceuticals (stock code: 688176.SH), a global, innovative pharmaceutical company focusing on genitourinary tumors and women's health, announced that its independently developed, portable, flexible blue light cystoscope APLD-2304 has recently received the EU MDR CE mark, granting market access in the EU. APLD-2304 is the world's first portable, flexible, single-use blue light cystoscope, developed by the company to meet the clinical needs and usage scenarios for bladder cancer diagnosis and follow-up monitoring[1]. Driven by an aging population and high smoking rates, Europe faces a high annual incidence of bladder cancer, exceeding 130,000 new cases[2]. The high recurrence rate of the disease creates a large unmet need for long-term postoperative patient monitoring. APLD-2304 leverages the advantage of blue light imaging to identify tiny lesions and carcinoma in situ, and has significant potential in the bladder cancer monitoring market. In clinical practice in Europe and the US, white light cystoscopy is often used for the diagnosis and follow-up of bladder cancer. However, it often fails to detect flat or small peripheral lesions in the early stage, leading to low detection rates and high recurrence rates. The company's APLD 2304, used in combination with a blue light imaging agent Hexvix®, forms an integrated diagnostic solution for bladder cancer drugs. This solution improves the detection rate of bladder cancer, reduces the recurrence rate for patients, and its portable, flexible, sterile single-use design provides greater convenience for doctors, improves patient comfort during surgical procedures, and reduces the risk of cross-infection. This CE certification for APLD 2304 was issued by the EU's notified body (BSI Group The Netherlands B.V.) in accordance with the certification rules of the Medical Device Regulation (MDR), along with a quality system certificate according to ISO 13485:2016. This is the first time a company-developed product has received regulatory registration in the EU, meaning that Asieris has established a quality management system for medical devices that complies with EU MDR requirements. APLD 2304 meets the latest criteria for market access in the EU and can be sold in regions that recognize EU medical device regulations. In addition, APLD-2304 has full independent intellectual property rights, and several patent applications for this product have been filed both nationally and internationally. Richard Zhao, Senior Vice President of Business Development at Asieris Pharmaceuticals, stated: "The EU CE mark for APLD 2304 is an important step in our strategic focus on specialized clinical fields and our comprehensive planning for holistic bladder cancer treatment. It also underscores Asieris’ strong commitment to addressing critical unmet global clinical needs. We will continue to drive the development of clinical treatment protocols, deliver innovative solutions for patients, and elevate the diagnostic and therapeutic standards for bladder cancer."
- ·3 päivää sittenCan someone give me motivation to stay🙏 it's a bit dark here these days- Reclassification in the USA will make the available market 12x larger. - New 4K HD-flex scope ready from 2027. - AssureMDx sales from 2027, and has several viable paths to reimbursement during 2027. - Cevira sales broadly underway in China with reimbursement most likely in place from January 2027. Approval in Europe in 2027. - Insiders and largest owner are increasing their positions after Asieris files a counterclaim. Should say enough about what they think it's heading towards. - After many years of lukewarm guidances from management, they have finally guided "high-teens" to 25% annual growth, and this was excluding reclassification. Find it very exciting to be PHO-invested at the moment.
- ·24.8.Things are loosening up soon for PHO. Downgrade in US As well as important validations of Cevira are the start of a strong repricing https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2026.1899399/full
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt